Genomic Health, Inc.
GHDX
GHDX was delisted on the 7th of November, 2019.
221 hedge funds and large institutions have $2.44B invested in Genomic Health, Inc. in 2019 Q3 according to their latest regulatory filings, with 59 funds opening new positions, 48 increasing their positions, 84 reducing their positions, and 53 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
19% more capital invested
Capital invested by funds: $2.06B → $2.44B (+$383M)
11% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 53
3% more funds holding
Funds holding: 215 → 221 (+6)
43% less repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 84
52% less call options, than puts
Call options by funds: $1.5M | Put options by funds: $3.13M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$104M |
| 2 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$54.2M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$38.8M |
| 4 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$33.2M |
| 5 |
IA
IndexIQ Advisors
New York
|
+$30.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$45.2M |
| 2 |
Man Group
London,
United Kingdom
|
-$44M |
| 3 |
Millennium Management
New York
|
-$41M |
| 4 |
Goldman Sachs
New York
|
-$29.2M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$27.2M |
GHDX Hedge Fund Activity: Q3 2019 in Review
221 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Genomic Health, Inc. (GHDX) for Q3 2019, worth a combined $2.44B — up 19% from $2.06B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new GHDX positions and 53 closed out — a net gain of 6 holders — while 48 added to existing stakes and 84 trimmed.
The largest buyer was BlackRock, adding an estimated $104M. The largest seller was Deutsche Bank, cutting an estimated $45.2M.
- 221 institutional investors held Genomic Health, Inc. (GHDX) as of Q3 2019, up from 215 in Q2 2019.
- Funds reported $2.44B of Genomic Health, Inc. stock for Q3 2019, up 19% quarter-over-quarter.
- 59 funds opened new Genomic Health, Inc. positions in Q3 2019 and 53 closed out, a net change of +6 holders.
- The largest Genomic Health, Inc. buyer in Q3 2019 was BlackRock, an estimated $104M added.
- The largest Genomic Health, Inc. seller in Q3 2019 was Deutsche Bank, an estimated $45.2M sold.
Based on aggregated 13F filings for Q3 2019.